NEWS HIGHLIGHTS
Published Studies Related to Hydralazine
Hydralazine for essential hypertension. [2011.11.09] CONCLUSIONS: Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. Furthermore, its effect on clinical outcomes remains uncertain.
Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. [2011.11] Intravenous hydralazine is a commonly administered arteriolar vasodilator that is effective for hypertensive emergencies associated with pregnancy...
Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. [2011.01] We evaluated 16 pregnant women with gestational age between 20 and 32 weeks in acute severe hypertension which were randomly allocated to receive either hydralazine or labetalol. Blood pressure and Doppler ultrasound parameters from maternal uterine and fetal middle cerebral and umbilical arteries were assessed during acute severe hypertension and after treatment...
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. [2010.10.08] The reversing of epigenetic aberrations using the inhibitors of DNA methylation and histone deacetylases may have therapeutic value in cervical cancer... Molecular correlates with response and survival from this trial are pending to analyze.
Hydralazine for essential hypertension. [2010.08.04] CONCLUSIONS: Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. Furthermore, its effect on clinical outcomes remains uncertain.
Clinical Trials Related to Hydralazine
Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD [Not yet recruiting]
This study is a pilot study designed to compare the safety and cardiovascular effects of 26
weeks of combination hydralazine/isorsorbide dinitrate therapy with amlodipine therapy in
patients receiving chronic hemodialysis.
The investigators hypothesize that treatment of chronic hemodialysis (ESRD) patients with a
combination of hydralazine/isosorbide dinitrate compared with amlopdipine is safe and that
it will improve heart function as well blood flow/blood vessel supply.
Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure [Active, not recruiting]
To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes,
symptoms, cardiac parameters and functional status of African patients hospitalized with AHF
and left ventricular dysfunction during 24 weeks of therapy.
Administration of hydralazine/nitrates will be superior to placebo administration in
reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain
natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular
dysfunction.
Hydralazine Valproate for Ovarian Cancer [Recruiting]
The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian
cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or
gemcitabine, however, the results need to be improved. Epigenetic aberrations play an
important role in cancer progression by silencing growth regulatory genes and there is now
evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity
of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate
plus topotecan over placebo plus topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase
progression-free survival from 6 to 9 months as compared with the same regimen of
chemotherapy plus placebo.
Hydralazine as Demethylating Agent in Breast Cancer [Withdrawn]
This study will be conducted as a phase I/II clinical trial. In addition to determining the
maximum tolerated dose (MTD) of hydralazine, the phase I trial will be performed to identify
unexpected toxicities that may occur when hydralazine is used in conjunction with
neoadjuvant chemotherapy in normotensive women with breast cancer. Once the phase I trial
is successfully completed, the phase II trial to evaluate the efficacy of hydralazine in
producing a demethylation effect will begin.
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy [Completed]
Hypertensive crisis (defined as a systolic pressure > 160mmHg or a diastolic pressure >
110mmHg) in patients with a hypertensive disorder of pregnancy is a serious complication
with severe and even deadly consequences. The management in this population had been
studied, but no consensus has been reached with regards to which treatment is better. Our
study will compare two drugs: Hydralazine and Labetalol for the management of hypertensive
crisis.
|